The predictive role of biochemical markers on outcomes of severe COVID-19 patients admitted to intensive care unit.

IF 2 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Medical Biochemistry Pub Date : 2023-08-25 DOI:10.5937/jomb0-40641

Bosa Mirjanić-Azarić, Ivana Pejić, Smiljana Mijić, Aleksandra Pejčić, Anita Đurđević-Svraka, Dragan Svraka, Darija Knežević, Tatjana Milivojac, Nataša Bogavac-Stanojević

{"title":"The predictive role of biochemical markers on outcomes of severe COVID-19 patients admitted to intensive care unit.","authors":"Bosa Mirjanić-Azarić, Ivana Pejić, Smiljana Mijić, Aleksandra Pejčić, Anita Đurđević-Svraka, Dragan Svraka, Darija Knežević, Tatjana Milivojac, Nataša Bogavac-Stanojević","doi":"10.5937/jomb0-40641","DOIUrl":null,"url":null,"abstract":"Background: The pandemic of severe acute respiratory syndrome by coronavirus 2 (SARS-CoV-2) is a multi-system disease caused by a diffuse systemic process involving a complex interaction of the inflammatory, immunological and coagulative cascades. This study aims to identify the most effective biomarkers to predict poor outcome in intensive care unit (ICU) patients with severe COVID-19 disease.Methods: A single-centre retrospective observational study enrolled 69 deceased and 20 recovered patients treated in the ICU of the General Hospital Gradiska in the period from March 1, 2021. until April 1, 2022. We evaluated the leukocytes (WBC), lymphocytes (LYM), neutrophils (NEU), platelets (PLT), haemoglobin, neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In addition, we evaluated the IL-6, ferritin, CRP, D-dimer, magnesium, bilirubin and lactate dehydrogenase.","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"42 3","pages":"513-523"},"PeriodicalIF":2.0000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5937/jomb0-40641","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The pandemic of severe acute respiratory syndrome by coronavirus 2 (SARS-CoV-2) is a multi-system disease caused by a diffuse systemic process involving a complex interaction of the inflammatory, immunological and coagulative cascades. This study aims to identify the most effective biomarkers to predict poor outcome in intensive care unit (ICU) patients with severe COVID-19 disease.

Methods: A single-centre retrospective observational study enrolled 69 deceased and 20 recovered patients treated in the ICU of the General Hospital Gradiska in the period from March 1, 2021. until April 1, 2022. We evaluated the leukocytes (WBC), lymphocytes (LYM), neutrophils (NEU), platelets (PLT), haemoglobin, neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In addition, we evaluated the IL-6, ferritin, CRP, D-dimer, magnesium, bilirubin and lactate dehydrogenase.

Abstract Image

查看原文本刊更多论文

生化标志物对重症监护病房收治的重症新冠肺炎患者预后的预测作用。

背景：冠状病毒2型严重急性呼吸系统综合征（严重急性呼吸综合征冠状病毒2型）是一种多系统疾病，由炎症、免疫和凝血级联反应的复杂相互作用引起。本研究旨在确定最有效的生物标志物，以预测重症新冠肺炎重症监护室（ICU）患者的不良结局。方法：一项单中心回顾性观察性研究纳入了自2021年3月1日起在格拉迪斯卡综合医院ICU接受治疗的69名死者和20名康复患者。至2022年4月1日。我们评估了白细胞（WBC）、淋巴细胞（LYM）、嗜中性粒细胞（NEU）、血小板（PLT）、血红蛋白、中性粒细胞淋巴细胞比率（NLR）、血小板淋巴细胞比率（PLR）和全身免疫炎症指数（SII）。此外，我们还评估了IL-6、铁蛋白、CRP、D-二聚体、镁、胆红素和乳酸脱氢酶。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medical Biochemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

3.00

自引率

12.00%

发文量

审稿时长

>12 weeks

期刊介绍： The JOURNAL OF MEDICAL BIOCHEMISTRY (J MED BIOCHEM) is the official journal of the Society of Medical Biochemists of Serbia with international peer-review. Papers are independently reviewed by at least two reviewers selected by the Editors as Blind Peer Reviews. The Journal of Medical Biochemistry is published quarterly. The Journal publishes original scientific and specialized articles on all aspects of clinical and medical biochemistry, molecular medicine, clinical hematology and coagulation, clinical immunology and autoimmunity, clinical microbiology, virology, clinical genomics and molecular biology, genetic epidemiology, drug measurement, evaluation of diagnostic markers, new reagents and laboratory equipment, reference materials and methods, reference values, laboratory organization, automation, quality control, clinical metrology, all related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry deal with the study of normal and pathologic processes in human beings.